PIA
TBPH icon

Piedmont Investment Advisors’s Theravance Biopharma TBPH Stock Holding History

Piedmont Investment Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-744
Closed -$17K – 2132
2018
Q2 		$17K Buy
+744
New +$17.7K ﹤0.01% 1638

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Piedmont Investment Advisors's TBPH Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Theravance Biopharma (TBPH) in Q3 2018, closing a stake of 744 shares — an estimated $17K sold.

Piedmont Investment Advisors first reported a position in TBPH in Q2 2018 and held it in 1 quarter. The position peaked at $17K in Q2 2018. 93 funds tracked by Wall St. Rank hold TBPH as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Theravance Biopharma position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 744 Theravance Biopharma shares in Q3 2018, an estimated $17K.
  • Piedmont Investment Advisors first reported a position in Theravance Biopharma in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Theravance Biopharma position peaked at $17K in Q2 2018.
  • 93 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.